Two phase II clinical trials that aimed to examine the efficiency of the HIF PHD inhibitors, Vadadustat and Desidustat, to prevent the progression of ARDS in hospitalised COVID-19 patients have been completed and their results are awaited [92,93]. This evidence concerns the gene PDC and COVID-19.